Literature DB >> 7378259

Accumulation of debrisoquine by platelets in vivo: a model of events at the peripheral adrenergic neurone.

J H Silas, G T Tucker, A J Smith, N R Fieller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7378259      PMCID： PMC1429981          DOI： 10.1111/j.1365-2125.1980.tb01071.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  19 in total

1.  Catecholamine depletion and adrenergic neurone blockade: studies with debrisoquine.

Authors:  M I Robertson; E T Abbs
Journal:  J Neurochem       Date:  1971-10       Impact factor: 5.372

2.  Uptake of debrisoquin and guanethidine by human blood platelets.

Authors:  D J Boullin; R A O'Brien
Journal:  J Pharm Pharmacol       Date:  1968-05       Impact factor: 3.765

3.  The binding of imipramine to the outer membrane of blood platelets.

Authors:  D J Boullin; R A O'Brien
Journal:  J Pharm Pharmacol       Date:  1968-07       Impact factor: 3.765

4.  The release of guanethidine and bethanidine by splenic nerve stimulation: a quantitative evaluation showing dissociation from adrenergic blockade.

Authors:  D G Shand; D H Morgan; J A Oates
Journal:  J Pharmacol Exp Ther       Date:  1973-01       Impact factor: 4.030

5.  Accumulation of debrisoquin-14C by the human platelet.

Authors:  R Pocelinko; H M Solomon
Journal:  Biochem Pharmacol       Date:  1970-03       Impact factor: 5.858

6.  The influence of debrisoquin on the accumulation and metabolism of biogenic amines by the human platelet, in vivo and in vitro.

Authors:  H M Solomon; C Ashley; N Spirt; W B Abrams
Journal:  Clin Pharmacol Ther       Date:  1969 Mar-Apr       Impact factor: 6.875

7.  On the physiological disposition and possible mechanism of the antihypertensive action of debrisoquin.

Authors:  M A Medina; A Giachetti; P A Shore
Journal:  Biochem Pharmacol       Date:  1969-04       Impact factor: 5.858

8.  Pharmacokinetics of bethanidine in hypertensive patients.

Authors:  D Shen; M Gibaldi; A Israili; G Bellward; R Cunningham; M Throne; P Dayton; J McNay
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

9.  Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man.

Authors:  J R Mitchell; J H Cavanaugh; L Arias; J A Oates
Journal:  J Clin Invest       Date:  1970-08       Impact factor: 14.808

10.  The accumulation of guanethidine by human blood platelets.

Authors:  D J Boullin; R A O'Brien
Journal:  Br J Pharmacol       Date:  1969-01       Impact factor: 8.739
View more
  2 in total

1.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

Authors:  C J Speirs; S Murray; A R Boobis; C E Seddon; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

2.  Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.

Authors:  C Nordin; B Siwers; J Benitez; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.